Apollo Therapeutics Partners with the University of Oxford to Enhance Drug Discovery and Development
Monday, July 22, 2024
The University of Oxford and Apollo Therapeutics have launched a new partnership focused on drug discovery and development, aiming to translate Oxford’s cutting-edge biomedical research into advanced therapies. As part of this collaboration, Apollo will evaluate and prioritize novel therapeutic targets identified by Oxford’s researchers to determine their potential as new medicines. In exchange, Oxford will gain access to Apollo’s expertise in drug development and funding, which will enhance the availability of clinical trials and speed up the path to market for new treatments.
This partnership leverages Oxford’s exceptional research capabilities alongside Apollo’s drug discovery and development skills. The goal is to create new medicines in fields like oncology and immunological and inflammatory disorders, potentially setting new standards in global healthcare.
Peter Kyle, Science and Technology Secretary, emphasized the significance of this collaboration in using life sciences to transform UK healthcare and drive economic growth. He highlighted how industry-academic partnerships, supported by government efforts, can lead to significant medical advancements.
Professor Chas Bountra, Pro-Vice Chancellor for Innovation at the University of Oxford, expressed enthusiasm about the collaboration, noting the potential for transforming patient care through Apollo’s resources and expertise.
This agreement marks Apollo’s sixth partnership with a major academic institution. Apollo's focus on translating research discoveries into new drugs is reinforced by this collaboration with Oxford, adding to their existing partnerships with institutions such as the University of Cambridge, Imperial College London, University College London, King’s College London, and the Institute of Cancer Research.
Dr. Richard Mason, CEO of Apollo Therapeutics, commended Oxford’s top-tier research standing and the opportunity to work with a leading institution to advance drug development.
Dr. Mairi Gibbs, CEO of Oxford University Innovation, highlighted the importance of supporting researchers with funding and expertise to accelerate the development of early-stage drug programs. This collaboration aims to speed up the process of turning innovative research into life-saving medicines for patients in need.
Source: businesswire.com
